NR4A2 and neoplasm: To determine the in vivo efficacy of NR4A2/hA1R engineered CAR T cells, 5x10e6 anti-HER2 CAR T cells or 15×10e6 anti-Lewis Y CAR T cells were adoptively transferred to treat MDA-MB231 breast (Fig. 4A) or OVCAR-3 ovarian (Fig. 4B) tumor bearing mice respectively.